Evoke Pharma Inc (EVOK)
4.35
+0.05
(+1.16%)
USD |
NASDAQ |
Nov 14, 12:31
Evoke Pharma Cash from Operations (Quarterly): -0.8206M for June 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -0.8206M |
| March 31, 2024 | -2.579M |
| December 31, 2023 | -1.106M |
| September 30, 2023 | -1.042M |
| June 30, 2023 | -1.206M |
| March 31, 2023 | -1.631M |
| December 31, 2022 | -2.506M |
| September 30, 2022 | -1.101M |
| June 30, 2022 | -1.374M |
| March 31, 2022 | -1.615M |
| December 31, 2021 | -1.997M |
| September 30, 2021 | -5.892M |
| June 30, 2021 | -1.510M |
| March 31, 2021 | -2.953M |
| December 31, 2020 | -1.712M |
| September 30, 2020 | -1.810M |
| June 30, 2020 | -1.556M |
| March 31, 2020 | -1.552M |
| December 31, 2019 | -1.148M |
| September 30, 2019 | -1.059M |
| June 30, 2019 | -1.628M |
| March 31, 2019 | -1.927M |
| December 31, 2018 | -1.249M |
| September 30, 2018 | -1.150M |
| June 30, 2018 | -1.762M |
| Date | Value |
|---|---|
| March 31, 2018 | -2.818M |
| December 31, 2017 | -2.734M |
| September 30, 2017 | -2.200M |
| June 30, 2017 | -2.096M |
| March 31, 2017 | -1.687M |
| December 31, 2016 | -1.370M |
| September 30, 2016 | -2.418M |
| June 30, 2016 | -2.230M |
| March 31, 2016 | -2.690M |
| December 31, 2015 | -2.452M |
| September 30, 2015 | -2.504M |
| June 30, 2015 | -2.544M |
| March 31, 2015 | -2.995M |
| December 31, 2014 | -2.521M |
| September 30, 2014 | -3.912M |
| June 30, 2014 | -3.068M |
| March 31, 2014 | -2.001M |
| December 31, 2013 | -1.889M |
| September 30, 2013 | -0.2747M |
| June 30, 2013 | -0.4298M |
| March 31, 2013 | -0.4465M |
| December 31, 2012 | -0.6528M |
| September 30, 2012 | -0.3015M |
| June 30, 2012 | -0.348M |
| March 31, 2012 | -0.4476M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-5.892M
Minimum
Sep 2021
-0.8206M
Maximum
Jun 2024
-1.848M
Average
-1.556M
Median
Jun 2020
Cash from Operations (Quarterly) Benchmarks
| Repligen Corp | 42.19M |
| Eli Lilly and Co | 3.712B |
| MEI Pharma Inc | -18.00M |
| Revance Therapeutics Inc | -41.09M |
| NovaBay Pharmaceuticals Inc | -0.578M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 0.2957M |
| Free Cash Flow | -5.548M |
| Free Cash Flow Per Share (Quarterly) | -7.222 |
| Free Cash Flow to Equity (Quarterly) | -0.8206M |
| Free Cash Flow Yield | -357.3% |